The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran.
EAVA
Egypt
Inclisiran
Journal
Cardiology and therapy
ISSN: 2193-8261
Titre abrégé: Cardiol Ther
Pays: England
ID NLM: 101634495
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
11
07
2022
accepted:
16
08
2022
pubmed:
3
9
2022
medline:
3
9
2022
entrez:
2
9
2022
Statut:
ppublish
Résumé
Elevation of low-density lipoprotein cholesterol (LDL-c) is still a hugely unmet need in the reduction of atherosclerotic cardiovascular disease. In the published CardioRisk project in Egypt, up to 71% of female participants had dyslipidemia. Control of LDL-c levels and thus improvement of hyperlipidemia is quite often very difficult. With the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the decrease of significant cardiac adverse events, the patient control rate, and the death rate have all been improved. Inhibition of the formation of PCSK9 through inclisiran, which is a novel method of reducing LDL-c and is only given twice per year, seems alluring. After revision of published data, we analyzed the potential advantages of the use of inclisiran. The Egyptian Association for Vascular Biology and Atherosclerosis (EAVA) analyzed the data necessary for obtaining clear indications for the usage of inclisiran. We propose the addition of inclisiran to statins with or without ezetimibe for patients with documented atherosclerotic cardiovascular disease (ASCVD) or similar risk, familial hypercholesterolemia (FH) with another major risk factor, and very high and high risk diabetes mellitus, who did not reach LDL-c goals and/or with true statin intolerance. Inclisiran is also recommended as upfront therapy, with triple combination, in extreme risk subjects such as those with post acute coronary syndromes (ACS).
Sections du résumé
BACKGROUND
BACKGROUND
Elevation of low-density lipoprotein cholesterol (LDL-c) is still a hugely unmet need in the reduction of atherosclerotic cardiovascular disease. In the published CardioRisk project in Egypt, up to 71% of female participants had dyslipidemia. Control of LDL-c levels and thus improvement of hyperlipidemia is quite often very difficult. With the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the decrease of significant cardiac adverse events, the patient control rate, and the death rate have all been improved. Inhibition of the formation of PCSK9 through inclisiran, which is a novel method of reducing LDL-c and is only given twice per year, seems alluring. After revision of published data, we analyzed the potential advantages of the use of inclisiran.
CONCLUSION
CONCLUSIONS
The Egyptian Association for Vascular Biology and Atherosclerosis (EAVA) analyzed the data necessary for obtaining clear indications for the usage of inclisiran. We propose the addition of inclisiran to statins with or without ezetimibe for patients with documented atherosclerotic cardiovascular disease (ASCVD) or similar risk, familial hypercholesterolemia (FH) with another major risk factor, and very high and high risk diabetes mellitus, who did not reach LDL-c goals and/or with true statin intolerance. Inclisiran is also recommended as upfront therapy, with triple combination, in extreme risk subjects such as those with post acute coronary syndromes (ACS).
Identifiants
pubmed: 36053454
doi: 10.1007/s40119-022-00277-3
pii: 10.1007/s40119-022-00277-3
pmc: PMC9652189
doi:
Types de publication
Letter
Langues
eng
Pagination
461-471Informations de copyright
© 2022. The Author(s).
Références
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205.
doi: 10.1016/j.atherosclerosis.2019.08.014
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.
doi: 10.1093/eurheartj/ehx144
pubmed: 28444290
pmcid: 5837225
Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010;376(9753):1670–81.
doi: 10.1016/S0140-6736(10)61350-5
pubmed: 21067804
Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: a statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021;325:99–109. https://doi.org/10.1016/j.atherosclerosis.2021.03.039 .
doi: 10.1016/j.atherosclerosis.2021.03.039
pubmed: 33892925
Ray KK, Reeskamp LF, Laufs U, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830–3. https://doi.org/10.1093/eurheartj/ehab718 .
doi: 10.1093/eurheartj/ehab718
pubmed: 34636884
Overview of the current status of familial hypercholesterolaemia care in over 60 countries—the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018;277:234–55. https://doi.org/10.1016/j.atherosclerosis.2018.08.051.Ff .
Reda A, et al. Prevalence of atherosclerosis risk factors in Egyptian patients with acute coronary syndrome: final data of the nationwide cross-sectional “CardioRisk” project. J Public Health Afr. 2021;11(2):1368. https://doi.org/10.4081/jphia.2020.1368 .
doi: 10.4081/jphia.2020.1368
pubmed: 33623654
pmcid: 7893316
Reda A, Abdel-Rehim AA, Afifi OSA. Centralized Pan-Middle East survey on the under-treatment of hypercholesterolemia: results from the CEPHEUS study in Egypt. Cardiol Ther. 2014;3(1–2):27–40.
doi: 10.1007/s40119-014-0031-x
pubmed: 25403341
pmcid: 4265229
Johanek E. High hopes for inclisiran. Will the third time be the charm for PCSK9 inhibition? Managed Healthcare. 2020;30(6).
Chamberlain AM, Gong Y, Shaw KM, et al. PCSK9 inhibitor use in the real world: data from the national patient-centered research network. J Am Heart Assoc. 2019;8(9): e011246. https://doi.org/10.1161/JAHA.118.011246 .
doi: 10.1161/JAHA.118.011246
pubmed: 31020929
pmcid: 6512121
Agarwala A, Quispe R, Goldberg AC, Michos ED. Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside. Drug Des Dev Ther. 2021;15:1955–63. https://doi.org/10.2147/DDDT.S251865 .
doi: 10.2147/DDDT.S251865
Chen P-Y, Gao W-Y, Liou J-W, Lin C-Y, Ming-Jiuan Wu, Yen J-H. Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia. Int J Mol Sci. 2021;22(14):7310. https://doi.org/10.3390/ijms22147310 .
doi: 10.3390/ijms22147310
pubmed: 34298929
pmcid: 8304944
Kosmas CE, Estrella AM, Sourlas A, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 2018;6(3):63. https://doi.org/10.3390/diseases6030063 .
doi: 10.3390/diseases6030063
pmcid: 6163360
Ding Z, Pothineni NVK, Goel A, Lüscher TF, Mehta JL. PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1. Cardiovasc Res. 2020;116:908–15.
doi: 10.1093/cvr/cvz313
pubmed: 31746997
Tuñón J, Badimón L, Bochaton-Piallat M-L, et al. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res. 2019;115:10–9.
doi: 10.1093/cvr/cvy293
pubmed: 30534957
Bernelot Moens SJ, Neele AE, Kroon J, et al. PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J. 2017;8:1584–93.
doi: 10.1093/eurheartj/ehx002
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. https://doi.org/10.1056/NEJMoa1912387 .
doi: 10.1056/NEJMoa1912387
pubmed: 32187462
Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–30. https://doi.org/10.1056/NEJMoa1913805 .
doi: 10.1056/NEJMoa1913805
pubmed: 32197277
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.
doi: 10.1056/NEJMoa1615664
pubmed: 28304224
Schwartz GG, Steg M, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.
doi: 10.1056/NEJMoa1801174
pubmed: 30403574
Cannon CP, Blazing MA, Guigliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Eng J Med. 2015;372:2387–97.
doi: 10.1056/NEJMoa1410489
Hagiwara N, Kawada-Watanabe E, Koyonagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomised trial. Eur Heart J. 2017;38:2264–75.
doi: 10.1093/eurheartj/ehx162
pubmed: 28430910
pmcid: 5837267
Preiss D, Tobert JA, Hovingh GK, et al. Lipid-modifying agents, from statins to PCSK9 inhibitors. J Am Coll Cardiol. 2020;75:1945–55.
doi: 10.1016/j.jacc.2019.11.072
pubmed: 32327106
Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins; a systematic review. J Clin Lipidol. 2010;4:462–71.
doi: 10.1016/j.jacl.2010.08.026
pubmed: 21122692
Hines DM, Rane P, Patel J, et al. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors. Vasc Health Risk Manag. 2018;14:409–18.
doi: 10.2147/VHRM.S180496
pubmed: 30573963
pmcid: 6292243
Arrieta A, Page TF, Valedar E, et al. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS ONE. 2017;12: e0169761.
doi: 10.1371/journal.pone.0169761
pubmed: 28081164
pmcid: 5232345
Introducing inclisiran—a partnership between the NHS and industry to tackle cardiovascular disease. https://www.england.nhs.uk/aac/what-we-do/introducing-revolutionary-medicines-to-the-nhs/commercial-partnerships/ . Accessed August, 2022.
Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to PCSK9 inhibitor therapy. JAMA Cardiol. 2017;2:1217–25.
doi: 10.1001/jamacardio.2017.3451
pubmed: 28973087
pmcid: 5963012
Chi X, Gatti P, Papoian T. Safety of antisense oligonucleotide and siRNA-based therapeutics. Drug Discov Today. 2017;22:823–33.
doi: 10.1016/j.drudis.2017.01.013
pubmed: 28159625
ClinicalTrials.gov An extension trial of inclisiran compared to evolocumab in participants with cardiovascular disease and high cholesterol. https://clinicaltrials.gov/ct2/show/NCT03060577 . Accessed 19 May 2020.
FDAAA TrialsTracker NCT03060577: an overdue trial by The Medicines Company. http://fdaaa.trialstracker.net/trial/NCT03060577/ . Accessed 29 May 2020.
ClinicalTrials.gov A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). https://clinicaltrials.gov/ct2/show/NCT03705234?term=ORION+inclisiran . Accessed 5 May 2020.